-
Something wrong with this record ?
Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?
P. Witters, T. Honzik, E. Bauchart, R. Altassan, T. Pascreau, A. Bruneel, S. Vuillaumier, N. Seta, D. Borgel, G. Matthijs, J. Jaeken, W. Meersseman, D. Cassiman, L. Pascale de, E. Morava,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV16-31932A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
ProQuest Central
from 2011-01-01 to 2021-12-31
Health & Medicine (ProQuest)
from 2011-01-01 to 2021-12-31
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Child MeSH
- Phenotype MeSH
- Phosphotransferases (Phosphomutases) deficiency MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Child, Preschool MeSH
- Disease Progression MeSH
- Congenital Disorders of Glycosylation epidemiology physiopathology MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
PURPOSE: PMM2-CDG is the most common congenital disorder of glycosylation (CDG), which presents with either a neurologic or multisystem phenotype. Little is known about the longitudinal evolution. METHODS: We performed data analysis on PMM2-CDG patients' clinical features according to the Nijmegen CDG severity score and laboratory data. Seventy-five patients (28 males) were followed up from 11.0 ± 6.91 years for an average of 7.4 ± 4.5 years. RESULTS: On a group level, there was no significant evolution in overall clinical severity. There was some improvement in mobility and communication, liver and endocrine function, and strabismus and eye movements. Educational achievement and thyroid function worsened in some patients. Overall, the current clinical function, the system-specific involvement, and the current clinical assessment remained unchanged. On follow-up there was improvement of biochemical variables with (near) normalization of activated partial thromboplastin time (aPTT), factor XI, protein C, antithrombin, thyroid stimulating hormone, and liver transaminases. CONCLUSION: PMM2-CDG patients show a spontaneous biochemical improvement and stable clinical course based on the Nijmegen CDG severity score. This information is crucial for the definition of endpoints in clinical trials.
Biochemistry Department AP HP Bichat Hospital Paris France
Center for Human Genetics KU Leuven Leuven Belgium
Gastroenterology Hepatology and Metabolic Center University Hospitals Leuven Leuven Belgium
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006765
- 003
- CZ-PrNML
- 005
- 20200525131503.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41436-018-0301-4 $2 doi
- 035 __
- $a (PubMed)30293989
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Witters, Peter $u Pediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium. peter.witters@uzleuven.be. Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium. peter.witters@uzleuven.be.
- 245 10
- $a Long-term follow-up in PMM2-CDG: are we ready to start treatment trials? / $c P. Witters, T. Honzik, E. Bauchart, R. Altassan, T. Pascreau, A. Bruneel, S. Vuillaumier, N. Seta, D. Borgel, G. Matthijs, J. Jaeken, W. Meersseman, D. Cassiman, L. Pascale de, E. Morava,
- 520 9_
- $a PURPOSE: PMM2-CDG is the most common congenital disorder of glycosylation (CDG), which presents with either a neurologic or multisystem phenotype. Little is known about the longitudinal evolution. METHODS: We performed data analysis on PMM2-CDG patients' clinical features according to the Nijmegen CDG severity score and laboratory data. Seventy-five patients (28 males) were followed up from 11.0 ± 6.91 years for an average of 7.4 ± 4.5 years. RESULTS: On a group level, there was no significant evolution in overall clinical severity. There was some improvement in mobility and communication, liver and endocrine function, and strabismus and eye movements. Educational achievement and thyroid function worsened in some patients. Overall, the current clinical function, the system-specific involvement, and the current clinical assessment remained unchanged. On follow-up there was improvement of biochemical variables with (near) normalization of activated partial thromboplastin time (aPTT), factor XI, protein C, antithrombin, thyroid stimulating hormone, and liver transaminases. CONCLUSION: PMM2-CDG patients show a spontaneous biochemical improvement and stable clinical course based on the Nijmegen CDG severity score. This information is crucial for the definition of endpoints in clinical trials.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a vrozené poruchy glykosylace $x epidemiologie $x patofyziologie $7 D018981
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a fosfotransferasy (fosfomutasy) $x nedostatek $7 D017875
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Honzik, Tomas $u Department of Pediatrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Bauchart, Eric $u AP-HP, Necker University Hospital, French National Reference Centre for Inborn Errors of Metabolism, Paris, France.
- 700 1_
- $a Altassan, Ruqaiah $u Medical Genetic Department, Montréal Children Hospital, McGill University, Montreal, Canada. Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium. Department of Medical Genetics, King Faisal Specialist and Research Hospital, Riyadh, Saudi Arabia.
- 700 1_
- $a Pascreau, Tiffany $u AP-HP, Hôpital Necker, Service d'Hématologie Biologique, Paris, France. UMR_S1176, INSERM, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
- 700 1_
- $a Bruneel, Arnaud $u Biochemistry Department, AP-HP, Bichat Hospital, Paris, France. UMR INSERM 1193, Faculty of Pharmacy, Paris-Sud University, Paris, France.
- 700 1_
- $a Vuillaumier, Sandrine $u Biochemistry Department, AP-HP, Bichat Hospital, Paris, France.
- 700 1_
- $a Seta, Nathalie $u Biochemistry Department, AP-HP, Bichat Hospital, Paris, France. Biochemistry Department, Paris Descartes University, Bichat Hospital, Paris, France.
- 700 1_
- $a Borgel, Delphine $u AP-HP, Hôpital Necker, Service d'Hématologie Biologique, Paris, France. UMR_S1176, INSERM, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
- 700 1_
- $a Matthijs, Gert $u Center for Human Genetics, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Jaeken, Jaak $u Pediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium. Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Meersseman, Wouter $u Metabolic Center, University Hospitals Leuven, Leuven, Belgium. Department of General Internal Medicine, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Cassiman, David $u Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a Pascale de, Lonlay $u AP-HP, Necker University Hospital, French National Reference Centre for Inborn Errors of Metabolism, Paris, France.
- 700 1_
- $a Morava, Eva $u Pediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium. Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
- 773 0_
- $w MED00186213 $t Genetics in medicine : official journal of the American College of Medical Genetics $x 1530-0366 $g Roč. 21, č. 5 (2019), s. 1181-1188
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30293989 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525131503 $b ABA008
- 999 __
- $a ok $b bmc $g 1525623 $s 1096821
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 21 $c 5 $d 1181-1188 $e 20181008 $i 1530-0366 $m Genetics in medicine $n Genet Med $x MED00186213
- GRA __
- $a NV16-31932A $p MZ0
- LZP __
- $a Pubmed-20200511